<DOC>
	<DOCNO>NCT01954017</DOCNO>
	<brief_summary>The study conduct two part . Part A sequential dose escalation study determine safety tolerability two dos STP206 versus control . Part B evaluate safety NEC preventive efficacy STP206 VLBW ELBW neonate .</brief_summary>
	<brief_title>STP206 Prevention NEC</brief_title>
	<detailed_description />
	<mesh_term>Enterocolitis , Necrotizing</mesh_term>
	<mesh_term>Enterocolitis</mesh_term>
	<criteria>1 . Neonates birth weight 2000500g Part A 1500500g Part B 2 . Ability start treatment within four day birth . 3 . Gestational age 23 32 week birth 4 . Obtaining informed consent subject 's mother full understanding study purpose procedure . 5 . Parents agree allow Principal Investigator his/her staff follow procedure assessment require protocol 1 . Infants , high probability , early onset sepsis ( positive blood culture clinical/histological chorioamnionitis expectation empirical antimicrobial therapy â‰¥5 day ) 2 . Infants persistent pulmonary hypertension newborn ( PPHN ) 3 . Congenital chromosomal anomaly 4 . Congenital acquire gastrointestinal pathology preclude feed soon birth ( e.g . cleft lip exclusion criterion , duodenal atresia ) 5 . Infants extremis intensive care offer attend neonatologist ( e.g. , infant provide hospice/comfort care ) 6 . Other condition infant , opinion attend neonatologist , preclude participation 7 . Positive maternal HIV status 8 . Participation another interventional clinical trial For Part A study , follow additional exclusion criterion apply : 9 . Small gestational age neonate , i.e . neonate weigh less 10th percentile gestational age accord Estimated Fetal Weight Percentile Chart</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>4 Days</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>